Compare · BSX vs HTFL
BSX vs HTFL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $69.68B, about 15.9x HTFL ($4.39B).
- Over the past year, BSX is down 54.9% and HTFL is up 61.2% - HTFL leads by 116.1 points.
- HTFL has been more active in the news (17 items in the past 4 weeks vs 5 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 8 for HTFL).
- Company
- Boston Scientific Corporation
- Heartflow Inc.
- Price
- $48.09-0.42%
- $50.41+0.02%
- Market cap
- $69.68B
- $4.39B
- 1M return
- -0.71%
- +88.66%
- 1Y return
- -54.90%
- +61.16%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 17
- Recent ratings
- 25
- 8
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
Latest HTFL
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Chief Executive Officer Farquhar John C.M. sold $1,361,500 worth of shares (27,230 units at $50.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 360,814 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,470,420 worth of shares (32,676 units at $45.00) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 388,044 units (SEC Form 4)
- Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $380,099 worth of shares (9,219 units at $41.23) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $607,774 worth of shares (15,560 units at $39.06) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 420,720 units (SEC Form 4)
- SEC Form 144 filed by Heartflow Inc.
- SEC Form 144 filed by Heartflow Inc.
- SEC Form 10-Q filed by Heartflow Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.